# EDGAR Filing Document

**Accession Number:** 0000719135
**File Stem:** 0001493152-26-029081
**Filing Date:** 2026-6
**Character Count:** 17188
**Document Hash:** f1224f772ce2a01d2fe28a4c48ae15ec
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-029081.hdr.sgml**: 20260617

**ACCESSION NUMBER**: 0001493152-26-029081

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20260611

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260617

**DATE AS OF CHANGE**: 20260617

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Apyx Medical Corp
- **CENTRAL INDEX KEY:** 0000719135
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 112644611
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-31885
- **FILM NUMBER:** 261098319

**BUSINESS ADDRESS:**
- **STREET 1:** 5115 ULMERTON ROAD
- **CITY:** CLEARWATER
- **STATE:** FL
- **ZIP:** 33760
- **BUSINESS PHONE:** 7273842323

**MAIL ADDRESS:**
- **STREET 1:** 5115 ULMERTON ROAD
- **CITY:** CLEARWATER
- **STATE:** FL
- **ZIP:** 33760

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BOVIE MEDICAL Corp
- **DATE OF NAME CHANGE:** 20150319

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BOVIE MEDICAL CORP
- **DATE OF NAME CHANGE:** 19990216

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AN CON GENETICS INC
- **DATE OF NAME CHANGE:** 19920703

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

**June 11, 2026**

Date of Report (date of earliest event reported)

![](form8-k_001.jpg)

**APYX MEDICAL CORPORATION**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-31885** | **11-2644611** |
| (State or other jurisdiction<br> of incorporation or organization) | (Commission<br> File Number) | (I.R.S. Employer<br> Identification No.) |

---

**5115 Ulmerton Road, Clearwater, Florida 33760**

(Address of principal executive offices, zip code)

**(727) 384-2323**

Registrant's telephone number, including area code

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, par value $0.001 per share | APYX | Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

| | |
|:---|:---|
| **Item 1.01.** | **Entry into a Material Definitive Agreement.** |

---

On June 11, 2026, Apyx Medical Corporation (the "Company") entered into a letter agreement (the "Letter Agreement") with Stavros Vizirgianakis, the Chairman of the Company's Board of Directors (the "Board"), in connection with Mr. Vizirgianakis' appointment as Executive Chairman of the Board.

Pursuant to the Letter Agreement and his appointment as Executive Chairman, Mr. Vizirgianakis will provide strategic leadership and governance oversight, assist management with the execution of corporate initiatives, support investor engagement, advise on capital markets and corporate development matters, and engage in other such comparable duties. Mr. Vizirgianakis will not serve as an officer or employee of the Company and will not be designated as an "executive officer" of the Company for purposes of Rule 3b-7 under the Securities Exchange Act of 1934, as amended.

In connection with Mr. Vizirgianakis' appointment as Executive Chairman and in recognition of his service to the Company, the Board approved a grant to Mr. Vizirgianakis of 450,000 restricted stock units (the "RSUs") under the Company's 2023 Share Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs will vest as follows, subject to Mr. Vizirgianakis' continued service with the Company through the applicable vesting dates: (i) 150,000 RSUs vest immediately on June 11, 2026 (the "Grant Date"); (ii) 150,000 RSUs will begin vesting on the first anniversary of the Grant Date and will vest ratably over the 12-month period beginning on such date in equal monthly installments; and (iii) 150,000 RSUs will begin vesting on the second anniversary of the Grant Date and will vest ratably over the 12-month period beginning on such date in equal monthly installments. The RSUs will otherwise be subject to the terms and conditions of the Plan and the Letter Agreement.

The foregoing description of the Letter Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Letter Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

---

| | |
|:---|:---|
| **Item 9.01.** | **Financial Statements and Exhibits.** |

---

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 10.1 | [Letter Agreement between Company and Stavros Vizirgianakis, dated June 11, 2026.](ex10-1.htm) |
| 104 | Cover Page Interactive Data File embedded within the Inline XBRL document |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **APYX MEDICAL CORPORATION** | **APYX MEDICAL CORPORATION** |
| Date: June 17, 2026 | By: | */s/ Matthew Hill* |
|  | Name: | Matthew Hill |
|  | Title: | Chief Financial Officer, Secretary and Treasurer |

---

## Exhibit 10.1

**Exhibit 10.1**

**APYX MEDICAL CORPORATION**

**5115 Ulmerton Road**

**Clearwater, Florida 33760**

June 11, 2026

Stavros Vizirgianakis

C/O Apyx Medical Corporation

5115 Ulmerton Road

Clearwater, Florida 33760

Re: <u>Appointment as Executive Chairman</u>

Dear Stavros:

This letter agreement (this "<u>Agreement</u>") confirms the terms of your appointment as Executive Chairman of Apyx Medical Corporation, a Delaware corporation (the "<u>Company</u>"), and the grant to you of restricted stock units ("<u>RSUs</u>"), under the Company's 2023 Share Incentive Plan (the "<u>Plan</u>"). This Agreement, including the granting of the RSU Award (defined below), is being entered into and provided in recognition of your service to the Company and your expected continued contributions in the role of Executive Chairman.

&nbsp;&nbsp;&nbsp;&nbsp;1. **Appointment as Executive Chairman.** Effective as of June 11, 2026, you are appointed to serve as Executive
 Chairman of the Board of Directors (the " <u>Board</u> ") of the Company. In that
 capacity, you will perform such duties and responsibilities as are traditionally performed
 by an executive chairperson, including providing strategic leadership and governance oversight,
 assisting management with execution of corporate initiatives, capital raising efforts, supporting
 investor engagement, advising on capital markets and corporate development matters, and other
 such comparable duties.

&nbsp;&nbsp;&nbsp;&nbsp;2. **Continued Board Service.** Your appointment as Executive Chairman is in addition to your current
 service as a member of the Board. Nothing in this Agreement limits the rights of the Company's
 stockholders or the Board with respect to your continued service as a director or Executive
 Chairman in accordance with applicable law, the Company's certificate of incorporation,
 bylaws and corporate governance policies.

&nbsp;&nbsp;&nbsp;&nbsp;3. **Term; At-Will Service.** Your service as Executive Chairman will continue until terminated by
 either you or the Company at any time and for any reason, subject to applicable law and any
 rights you may have under this Agreement, the Plan or any other written agreement approved
 by the Board or the Compensation Committee of the Board (the " <u>Compensation Committee</u> ").
 Your appointment as Executive Chairman does not create any right to continued employment,
 service or engagement with the Company or any of its subsidiaries or affiliates.

&nbsp;&nbsp;&nbsp;&nbsp;4. **Compensation.** In consideration of your service as Executive Chairman, and subject to approval by the Board,
 you will receive the RSU Award described in **Section 5** below. You will not receive
 any cash compensation for your service as Executive Chairman, but will be reimbursed for
 reasonable and documented business expenses incurred in the performance of your duties, subject
 to the Company's expense reimbursement policies as in effect from time to time.

&nbsp;&nbsp;&nbsp;&nbsp;5. **RSU Award.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) **Grant.** Subject to approval by the Board, the Company hereby grants to you 450,000 RSUs (the " <u>RSU Award</u> "), effective as of June 11, 2026 (the " <u>Grant Date</u> "). Each
 RSU underlying the RSU Award represents the right to receive one (1) share of the Company's
 common stock, par value $0.001 per share (" <u>Common Stock</u> "), subject to
 the terms and conditions of this Agreement and the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) **Plan Incorporation.** The RSUs are granted under and subject to the terms and conditions of
 the Plan, which are incorporated into this Agreement by reference. By signing this Agreement,
 you acknowledge receipt of a copy of the Plan or access to the Plan, and agree to be bound
 by all terms and conditions of the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) **Vesting.** Subject to your continued service with the Company through each applicable vesting date,
 except as otherwise provided in this Agreement, the Plan or any other written agreement approved
 by the Board or Compensation Committee, the RSUs will vest as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. 150,000
 RSUs will vest immediately on the Grant Date;

ii. 150,000
 RSUs will begin vesting on the first (1<sup>st</sup>) anniversary of the Grant Date and will
 vest ratably over the 12-month period beginning on such date, in equal monthly installments;
 and

iii. 150,000
 RSUs will begin vesting on the second (2<sup>nd</sup>) anniversary of the Grant Date and
 will vest ratably over the 12-month period beginning on such date, in equal monthly installments.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) **Acceleration Upon Change of Control.** Notwithstanding the vesting schedule set forth above, upon the
 occurrence of a Change of Control, all then-unvested RSUs will immediately become fully vested
 as of immediately prior to, and contingent upon, the consummation of such Change of Control.
 For purposes of this Agreement, " <u>Change of Control</u> " means the occurrence
 of any transaction or series of related transactions pursuant to which any person or group
 acquires more than 50% of the outstanding voting power of the Company, a merger or consolidation
 of the Company in which the Company's stockholders immediately prior to such transaction
 do not own a majority of the voting power of the surviving or resulting entity immediately
 following such transaction, or the sale of all or substantially all of the Company's
 assets.

(e) **Termination of Service.** Except as otherwise provided in this Agreement, the Plan or any other written
 agreement approved by the Board or Compensation Committee, any unvested RSUs will be forfeited
 automatically without consideration upon termination of your service with the Company as
 Executive Chairman for any reason. For purposes of the RSUs, "service" means
 your continued service to the Company as Executive Chairman.

&nbsp;&nbsp;&nbsp;&nbsp;6. **Tax Matters; Withholding.** You are responsible for all federal, state, local and foreign taxes
 arising from the RSUs, the issuance of shares of Common Stock in settlement of the RSUs and
 any other compensation or benefits provided under this Agreement. The Company may satisfy
 any required tax withholding obligations in any manner permitted under the Plan and applicable
 law, including by withholding shares otherwise deliverable upon settlement of vested RSUs,
 withholding from other amounts payable to you, requiring a cash payment from you, or any
 combination of the foregoing. You acknowledge that the Company has not provided tax advice
 to you and that you have been advised to consult your own tax advisor regarding this Agreement
 and the RSUs.

&nbsp;&nbsp;&nbsp;&nbsp;7. **Section 409A.** This Agreement and the RSUs are intended to be exempt from, or comply with, Section
 409A of the Internal Revenue Code of 1986, as amended, including under the short-term deferral
 exemption, and shall be interpreted and administered accordingly. The Company makes no representation
 or warranty regarding the tax treatment of this Agreement or the RSUs.

&nbsp;&nbsp;&nbsp;&nbsp;8. **Compliance with Law.** The issuance of shares of Common Stock in settlement of the RSUs is subject
 to compliance with all applicable laws, rules and regulations, including securities laws
 and Nasdaq listing standards. The Company will not be required to issue any shares if such
 issuance would violate applicable law or any applicable Company policy. You acknowledge that
 the Company may be required to disclose the terms of this Agreement, your appointment as
 Executive Chairman and the RSU Award, and may be required to file this Agreement, in whole
 or in part, with the Securities and Exchange Commission, Nasdaq or other governmental or
 regulatory authorities. You consent to such disclosures and filings as the Company determines
 are required or advisable.

&nbsp;&nbsp;&nbsp;&nbsp;9. **Conflict with Plan.** In the event of any conflict between this Agreement and the Plan, the Plan
 will control, unless otherwise permitted by the Plan and expressly approved by the Board
 or Compensation Committee. Capitalized terms used but not defined in this Agreement have
 the meanings given to them in the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;10. **Entire Agreement; Amendments.** This Agreement, together with the Plan and any other written agreement
 expressly referenced herein, constitutes the entire agreement between you and the Company
 with respect to your appointment as Executive Chairman and the RSU Award described herein,
 and supersedes any prior or contemporaneous oral or written understandings with respect to
 such matters. This Agreement may be amended only by a written instrument signed by you and
 an authorized representative of the Company, except that the Company may make administrative
 or ministerial changes, or changes required to comply with applicable law, the Plan or Company
 policy, to the extent permitted by the Plan and applicable law.

&nbsp;&nbsp;&nbsp;&nbsp;11. **Governing Law.** This Agreement will be governed by and construed in accordance with the laws of
 the State of Delaware, without regard to conflicts of law principles that would result in
 the application of the laws of another jurisdiction.

&nbsp;&nbsp;&nbsp;&nbsp;12. **Counterparts; Electronic Signatures.** This Agreement may be executed in counterparts, each of which
 will be deemed an original and all of which together will constitute one and the same instrument.
 Signatures delivered by electronic means will be deemed effective for all purposes.

Please confirm your agreement with the foregoing by signing and returning this Agreement.

---

| | |
|:---|:---|
| Sincerely, | Sincerely, |
| **Apyx Medical Corporation** | **Apyx Medical Corporation** |
| By: | */s/ Charlie Goodwin* |
| Name: | Charlie Goodwin |
| Title: | Chief Executive Officer |

---

---

| | |
|:---|:---|
| Agreed and accepted: |  |
| */s/ Stavros Vizirgianakis* | |
| Stavros Vizirgianakis |  |

---